No Data
No Data
Stifel Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4
Stifel Nicolaus Keeps Their Buy Rating on Compugen (CGEN)
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
Express News | Shares of Compugen Down 3%, Iteos Therapeutics Down 6.1%, and Arcus Biosciences Down 3.8%
Roche's TIGIT therapy failed to achieve its main goal. Biotechnology stocks like Compugen (CGEN.US) suffered heavy losses before the market opened.
On Friday, following the failure of a similar drug being developed by Swiss pharmaceutical giant Roche in phase 2/3 clinical trials, the stock prices of some biotech companies developing a new type of anti-cancer drug (known as a new "anti-TIGIT therapy") have fallen significantly in pre-market trading. Roche's stock price also fell in the European stock market on Thursday. Earlier, the company stated that tiragolumab, its anti-TIGIT treatment drug as part of a frontline drug combination, was used in the SKYSCRAPER study for non-squamous non-small-cell lung cancer.
Roche's Setback in Lung Cancer Trial Sends Anti-TIGIT Developers Lower